Business
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in
About this update from Cardiff Oncology, Inc.
[{"type":"image","alt":"Cardiff Oncology, Inc.","displaySize":"","headline":null,"caption":"Cardiff Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wD6rQtC_HUbA6JNQ3Eac3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71","width":300,"height":89}},"lazy":false},{"type":"text","content":"- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC –","length":234,"tagName":"p"},{"type":"text","content":"- Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC –","length":110,"tagName":"p"},{"type":"text","content":"- Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology –","length":194,"tagName":"p"},{"type":"text","content":"- Onvansertib continues to be safe and well-tolerated –","length":55,"tagName":"p"},{"type":"text","content":"- Company expects to provide final data and registrational plans in first half of 2026 –","length":88,"tagName":"p"},{"type":"text","content":"- Company to hold conference call today at 8:30 a.m. ET/5:30 a.m. PT -","length":70,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a positive update from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard of care (SoC) regimens (FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line (1L) RAS-mutated metastatic colorectal cancer (mCRC). In an intent-to-treat analysis, the clinical data show dose-dependent benefits across multiple efficacy measures in patients receiving onvansertib with FOLFIRI/bev compared to patients receiving either SoC regimen. In this trial, onvansertib with FOLF...